Surveyed Global Life Science Teams Expend Up To $30 Million in 2017 for Patient Adherence Activities

RESEARCH TRIANGLE PARK, NC—(Marketwired – June 14, 2017) – As increasing patient adherence efforts continue an upward trend in the pharmaceutical and healthcare industry, surveyed global life science firms report expanding patient adherence budgets in 2017, according new research by business intelligence firm Cutting Edge Information.

Data published in the study, Patient Adherence Program Planning: Drive Compliance to Improve Treatment Outcomes, revealed that a Top 10 pharma company reported the largest budget increase, growing from $10 million in 2015 to $30 million in 2017.

Additional data from same study found that smaller pharmaceutical companies surveyed report significantly smaller budgets. However, one Top 50 company and two small medical device companies expect budget increases in coming years.

“Patient adherence has been a growing interest within the life sciences industry for several years,” said Adam Bianchi, senior director of research at Cutting Edge Information. “To support these continuing — and in many cases, growing — patient–centered efforts, life science companies are increasing monetary resources to their marketed brands.”

Compared to their global counterparts, surveyed regional groups typically report much smaller budgets. According to the study, two of five teams report stable brand budgets from 2014 to 2017, including one Top 50 company, whose team reports a small growth from 2014 ($2 million) to 2015 ($2.1 million). Another small pharmaceutical company's team reports a brand budget of $500,000 across all four years.

One Top 50 company's regional team is an exception to the smaller regional budget trend; it reports the largest brand budget across all four years. The company reports a $35 million brand adherence budget for 2014, which is higher than the budget reported by the Top 10 company's global team mentioned before. However, this regional team's budget decreased by $20 million in the next year to only $15 million. The budget is expected to continue declining to only $10 million in 2017.

Patient Adherence Program Planning: Drive Compliance to Improve Treatment Outcomes, available at https://www.cuttingedgeinfo.com/product/patient–adherence–program–planning/, examines how pharmaceutical, biotechnology and other life science companies develop and support patient adherence topics. The report includes detailed benchmarking metrics and case studies of winning initiatives, including budgets, timing, outsourcing and vendor selection, as well as program channels — including digital and mobile resources — for new patient adherence initiatives.

The report is a decision support tool for life science companies seeking to implement or improve their approaches to patient adherence. The report is designed to help executives:

  • Develop a winning combination of patient adherence activities across a range of media
  • Take advantage of new patient adherence technologies and strategies, such as gamification
  • Benchmark budget and staffing resources for patient adherence initiatives
  • Discover industry trends and insights into new approaches for patient adherence programs

For more information about Cutting Edge Information's patient adherence research and to obtain a copy of Patient Adherence Program Planning: Drive Compliance to Improve Treatment Outcomes, please visit https://www.cuttingedgeinfo.com.

Image Available: http://www.marketwire.com/library/MwGo/2017/6/12/11G140927/Images/June_14_2017_–_PH226_–_Surveyed_Global_Life_Scienc–78f49fa1e42cb3dea53cf74081e3c83e.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/6/12/11G140927/Images/June_14_2017_–_PH226_–_Surveyed_Global_Life_Scienc–09052f61f34abed19bf034a3371535ae.jpg

MediaValet Announces Grant of Options

VANCOUVER, BC—(Marketwired – June 14, 2017) – MediaValet Inc. (TSX VENTURE: MVP) (the “Company”) announced today that it has issued 550,000 stock options to certain employees and directors of the Company. The options are being offered in conformance with TSX Venture Exchange regulations as incentive compensation. The options have a term of five years and an exercise price of $0.09 per share.

Following the issuance, the Company has 7,890,664 incentive stock options outstanding. As approved at the June 16, 2016 annual general meeting, the Company's Stock Option Plan allows the Board to issue the equivalent of up to 10% of the issued and outstanding share capital of the Company on a rolling basis.

About MediaValet, Inc.

MediaValet stands at the forefront of the cloud–based digital asset management industry. Built exclusively on Microsoft Azure and available on 34 highly secure and hyper scalable data centers around the world, MediaValet is uniquely equipped to meet the digital asset management needs of any organization, no matter its size, its industry or its location. Cutting–edge technology, exceptional product design, and unlimited friendly customer service are at the core of MediaValet's DNA — ensuring exceptional customer and user experiences are delivered at all times. Learn more at www.mediavalet.com.

Follow MediaValet: Blog, Twitter and LinkedIn

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”